Raymond James Downgrades POINT Biopharma Global to Market Perform
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Rahul Sarugaser has downgraded POINT Biopharma Global (NASDAQ:PNT) from Outperform to Market Perform.

October 06, 2023 | 9:06 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
POINT Biopharma Global has been downgraded by Raymond James from Outperform to Market Perform, which may impact its stock price.
Analyst ratings often influence the market's perception of a company. A downgrade from Outperform to Market Perform suggests that the analyst believes the company's stock will not outperform the market in the near future. This could lead to a decrease in demand for the stock and potentially a decrease in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100